Immunocore vs Novavax
IMCR and NVAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMCR and NVAX compare
Immunocore and Novavax are about the same size, with market caps of $1.5B and $1.4B.
Immunocore grew revenue faster over the last twelve months (13.1% versus −61.3% for Novavax).
Immunocore keeps more of each dollar of sales as profit, with a net margin of −7.5% compared with −18.6% at Novavax.
Immunocore scores higher on the StockData Score (7 against 5 for Novavax), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMCR | NVAX |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $1.4B |
| Share price | $29.94 | $8.53 |
| Change, 1 year | −15.2% | 18.4% |
| Change, 5 years | −21.4% | −95.6% |
| Beta (5Y) | 0.69 | 1.92 |
| Employees | 524 | 749 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 1 | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 3 (better) | 2 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.6× | 3.4× (better) |
| P/B | 3.7× | – |
| FCF yield | −1.2% | – |
| Fair value | $31.07 | – |
| Margin of safety | 3.6% | – |
| Growth | ||
| Revenue growth (TTM) | 13.1% (better) | −61.3% |
| Revenue growth, 5Y average | – | 18.8% |
| Net income growth (TTM) | – | −122% |
| EPS growth (TTM) | – | −127% |
| Profitability | ||
| Gross margin | 98.9% (better) | 78.0% |
| Operating margin | −6.8% (better) | −21.2% |
| Net margin | −7.5% (better) | −18.6% |
| FCF margin | −4.2% | – |
| Return on equity | −7.9% | – |
| Financial health | ||
| Interest coverage | −2.4× (better) | −4.0× |
| Current ratio | 4.62 (better) | 2.15 |
| Altman Z-score | 1.45 (better) | −5.94 |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 71.2% |
| Held by insiders | 15.5% | 9.2% |
| Insider net buying, 12 months | −$1.9M | – |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 30.9% |
Go deeper
- IMCR stock overview
- IMCR income statement
- IMCR valuation and score
- NVAX stock overview
- NVAX income statement
- NVAX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.